Możliwości zastosowania komórek macierzystych u pacjentów z chorobami genetycznymi. Część pierwsza – niektóre wskazania

*Dariusz Boruczkowski¹, Katarzyna Pawelec², Maciej Boruczkowski^{3, 4}, Piotr Michalski⁵

Summary
The report about first haematopoietic stem cells transplantation from cord blood was published in 1989. Since then, the major changes have occurred, based on scientific and technical developments. There is a potential limit (number of haematopoietic stem cells) for the widespread use of cord blood as a source of hematopoietic stem cells for marrow replacement in Poland. Ex-vivo expansion (outside of the Poland) proves usefulness in different clinical situation, involving treatment of grown-up children and adults. Transplantation, defined as an ex-vivo generated components, presents good approach and may open a promising new way for cell therapy in genetic diseases.
A new kind of stem cells population from i.e. human cord blood was described (mesenchymal cells) which can grow and can expand without losing pluripotency and can show differentiation into osteoblasts, chondroblasts, adipocytes, hematopoietic and neural cells too. New articles suggest that treatment by stem cells in for example retinitis pigmentosa, can produce retina functional recovery.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.